抑制FLT3信号抑制可消除阿片类药物耐受性和过敏症,同时保持疼痛缓解
Antoine Jouvenel1,2, Adrien Tassou1,2, Maxime Thouaye1,2
1Université de Montpellier, Montpellier, France.
Nature communications
|November 7, 2024
概括
在外围神经元中准fms类铁氨酸激酶受体3 (FLT3) 可以预防阿片类耐受性和过敏症. 将吗啡与FLT3抑制剂结合起来可以增强镇痛,减少副作用,提供更安全的慢性疼痛管理.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 阿片类药物是有效的止痛药,但会导致耐受性和过敏症,使慢性疼痛管理复杂化.
- 周围的片受体 (MOR) 调解了阿片类药物的止痛和不良影响.
- 目前的策略往往涉及剂量升级,增加风险.
研究的目的:
- 为了研究fms类铁氨酸激酶受体3 (FLT3) 在阿片类药物诱导的耐受性和过敏症中的作用.
- 探索FLT3抑制作为改善慢性疼痛阿片类药物治疗的策略.
主要方法:
- 使用男性动物模型进行慢性吗啡治疗.
- 检查了外围体感神经元中FLT3和MOR的共同表达.
- 评估FLT3抑制对循环腺单酸盐 (cAMP) 信号通路的影响.
- 在术后和炎症性疼痛模型中评估了与FLT3抑制剂同时使用吗啡的影响.
主要成果:
- 慢性吗啡增加了FLT3和MOR的共同表达.
- 抑制FLT3抑制了MOR诱导的cAMP通路过活化.
- 同时服用吗啡和FLT3抑制剂可以预防/抑制耐受性和过敏症.
- 这种组合增强了吗啡的止痛效果,但没有增加副作用.
结论:
- 周围体感神经元中的FLT3驱动了吗啡耐受性和过敏症.
- 抑制FLT3提供了一种加强阿片类药物止痛和减轻副作用的策略.
- 将吗啡与FLT3抑制剂结合在一起,为更安全的慢性疼痛管理提供了一个有希望的方法,可能减少阿片类药物的剂量和成风险.
相关概念视频
Analgesia and Pain Management
518
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
518
Opioid Analgesics: Synthetic and Semisynthetic Opioids
230
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
230
Opioid Receptors: Overview
538
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
538
Opioid Analgesics: Morphine and Other Natural Cogeners
185
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
185
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K


